
Increases Total Mineral Inventory: Provides Results of Updated Mineral Resource and Reserves
Increases Total Mineral Inventory: Provides Results of Updated Mineral Resource and Reserves
Serabi Gold plc ('Serabi' or the 'Company') (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, is pleased to announce updated Mineral Reserve estimates and Mineral Resource estimates for its Palito Mine, prepared in accordance with the standard of CIM and Canadian National Instrument 43-101, with an effective date of 1 April, 2025 as outlined below (all financial amounts are expressed in U.S. dollars unless otherwise indicated) .
HIGHLIGHTS Proven and Probable ('2P') Reserves totalling 162,600 ounces (706,000 tonnes at 7.2 g/t Au) compared to 206,400 ounces (824,800 tonnes @ 7.8 g/t Au) in July 2023.
Reserve life is equivalent to over six years of operations at current production levels, without considering conversion of additional mineral resources.
Measured and Indicated ('M&I') Resources of 388,400 ounces of contained gold (1,252,900 tonnes @ 9.6 g/t Au), a 3% increase compared to 377,800 (1,166,300 tonnes @ 10.1 g/t) in December 2023.
Inferred Resources of 163,900 ounces (690,200 tonnes @ 7.4 g/t Au), a 7% increase compared to 153,900 ounces (682,400 tonnes @ 7.0 g/t Au in July 2023).
NCL Ingeniería y Construcción SpA of Santiago de Chile ('NCL') is preparing this Mineral Resource and Mineral Reserve estimation together with a new 43-101 Technical Report which is expected to be issued within 45 days of the date of this release.
Mike Hodgson CEO commented:
'This updated Mineral Resource demonstrates Serabi's ability to replenish resources on a consistent basis. We have regularly maintained our ability to replace production with new resources and in this instance, the combined Measured, Indicated and the Inferred resource categories have increased by 4% since 2023. The Company has a strong track record of maintaining a ~500koz ounces total mineral inventory at the Palito Complex and this latest estimate is no different as we increase to 552koz. Within this mineral resource inventory, we have reported a 2P Mineral Reserve of ~163koz, equating to over six years of reserve life at current extraction rates, excluding any future resource to reserve conversion. For a narrow vein mine, this is a great position to be in. With São Chico on care and maintenance since 2022, the 2023 estimated resources and reserves have simply been restated here, albeit these resources and reserves were calculated at a more conservative gold price and exchange rate.
In early 2025 we embarked on a $9m brownfield surface exploration drill programme spread across the Palito Complex and Coringa, approximately 50% of this budget will be used at Palito to test extensions of known orebodies. As this drill programme did not commence until March, this updated resource estimate does not include results from the exploration programme. We therefore look forward to an update in early 2026, when we do expect to incorporate results from our 'aggressive' brownfield programme. In the meantime, this increase, which excludes the surface drill programme, is especially pleasing.'
The Mineral Reserve estimate was prepared by Mr Carlos Guzman of NCL Ingeniería y Construcción SpA, who is a Qualified Person under the Canadian National Instrument 43-101.
The Mineral Resource estimate was prepared by Mr Nicolas Fuster of NCL Ingeniería y Construcción SpA, who is a Qualified Person under the Canadian National Instrument 43-101.
Mineral Reserve Estimates
The updated Mineral Reserve estimates for the Palito Mine and the São Chico Mine are based on data as at 1st April 2025.
Table 1: Palito Complex Mineral Reserve Statement as of April 1, 2025 Mineral Reserve Statement for the Palito Complex (Palito and São Chico Mines) Palito São Chico Combined Tonnes Grade Contained Tonnes Grade Contained Tonnes Grade Contained (000's) (g/t Au) (000's oz) (000's) (g/t Au) (000's oz) (000's) (g/t Au) (000's oz) Proven 422.4 7.7 103.8 46.1 8.2 12.2 468.5 7.7 116.0 Probable 223.6 6.0 43.1 14.1 7.7 3.5 237.7 6.1 46.6 Total Reserves 645.9 7.1 147.0 60.2 8.1 15.6 706.1 7.2 162.6
Notes to Palito Complex Mineral Reserve Estimates Mineral Reserves have been rounded to reflect the relative accuracy of the estimates. Proven Mineral Reserves are reported within the Measured classification domain, and Probable Mineral Reserves are reported within the Indicated classification domain. Palito Mine Proven and Probable Mineral Reserves are inclusive of external mining dilution and mining loss and are reported at a cut-off grade of 3.98 g/t gold for Palito Mine and assuming an underground shrinkage mining scenario, a gold price of US$2,000/oz, a 5.5:1 Brazilian Real to U.S. Dollar exchange rate, and metallurgical recoveries of 93.2%. São Chico Mine Proven and Probable Mineral Reserves are inclusive of external mining dilution and mining loss and are reported at a cut-off grade of 4.0 g/t gold and assuming an underground shrinkage mining scenario, a gold price of US$1,800/oz, a 5.0:1 Brazilian Real to U.S. Dollar exchange rate, and metallurgical recoveries of 93.8%, as estimated in 2023 and re-stated in this release . Serabi is the operator and owns 100% of the Palito Mine such that gross and net attributable mineral reserves are the same. The mineral reserve estimate was prepared by NCL in accordance with the standard of CIM and NI 43-101, with an effective date of April 1, 2025, and audited and approved by Mr. Carlos Guzmán of NCL, who is a Qualified Person under NI 43-101.
Mineral Resource Estimates
The updated Mineral Resource estimates for the Palito Mine and the Sao Chico Mine are based on data as at 1st April 2025 and 31st July 2023, respectively.
Table 2: Mineral Resource Statement, Palito Mine as of April 1, 2025 Classification Tonnes Grade Contained (000's) (g/t Au) (000's) Measured 769 10.8 267.5 Indicated 333 7.7 82.5 Measured and Indicated 1,102 9.9 350.0 Inferred 682 7.4 161.8
Notes to Palito Mine Mineral Resource Statement Mineral Resources are not Mineral Reserves and have not demonstrated economic viability. Mineral Resources are reported inclusive of Mineral Reserves. Figures are rounded to reflect the relative accuracy of the estimates. Mineral Resources are reported within classification domains with no dilution applied at a cut-off grade of 2.92 g/t gold assuming an underground extraction scenario, a gold price of US$2,500/oz, metallurgical recovery of 95% and exchange rate of R$ 6.0/US$. Polygonal techniques were used for Resources estimates. The mineral resource estimate was prepared by NCL in accordance with the standard of CIM and NI 43-101, with an effective date of April 1, 2025, and audited and approved by Mr. Nicolas Fuster of NCL, who is a Qualified Person under NI 43-101.
Table 3: Mineral Resource Statement, São Chico Mine as of July 31, 2023 Classification Tonnes Grade Contained (000's) (g/t Au) (000's) Measured 123 8.1 31.9 Indicated 29 7.1 6.5 Measured and Indicated 151 7.9 38.4 Inferred 8 6.5 1.7
Notes to Mineral Resource Statement, São Chico Mine Mineral Resources are not Mineral Reserves and have not demonstrated economic viability. Mineral Resources are reported inclusive of Mineral Reserves. Figures are rounded to reflect the relative accuracy of the estimates. Mineral Resources are reported within classification domains with no dilution applied at a COG of 3.32 g/t gold assuming an underground extraction scenario, a gold price of US$1,950/oz, metallurgical recovery of 95% and exchange rate of R$ 5.5/US$3D block model used for Resource estimates. Polygonal techniques were used for Resources estimates.
Qualified Persons and Quality Control
The scientific and technical information contained in this news release pertaining to the Palito Complex has been reviewed and approved by the following Qualified Persons under National Instrument 43-101 – Standards of Disclosure for Mineral Projects ('NI 43-101'): Carlos Guzman,RM CMC, FAusIMM, NCL Ingeniería y Construcción SpA
Gustavo Tapia, RM CMC, Metallurgical and Process Consultant, GT Metallurgy
Nicolas Fuster, RM CMC, MAusIMM, NCL Ingeniería y Construcción SpA
The Qualified Persons have verified the information disclosed herein, including the sampling, preparation, security and analytical procedures underlying the information or opinions contained in this announcement in accordance with standards appropriate to their qualifications.
Technical Report
A Technical Report prepared by NCL Ingeniería y Construcción SpA. In accordance with NI 43-101 will be filed on SEDAR ( www.sedar.com ) within 45 days of this release as well as on the Company's website
About Serabi Gold plc
Serabi Gold plc is a gold exploration, development and production company focused on the prolific Tapajós region in Para State, northern Brazil. The Company has consistently produced 30,000 to 40,000 ounces per year with the Palito Complex and is planning to double production in the coming years with the construction of the Coringa Gold project. Serabi Gold plc recently made a copper-gold porphyry discovery on its extensive exploration licence. The Company is headquartered in the United Kingdom with a secondary office in Toronto, Ontario, Canada.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018.
The person who arranged for the release of this announcement on behalf of the Company was Andrew Khov, Vice President, Investor Relations & Business Development.
Enquiries
SERABI GOLD plc
Michael Hodgson t +44 (0)20 7246 6830
Chief Executive m +44 (0)7799 473621
Colm Howlin
Chief Financial Officer m +353 89 6078171
Andrew Khov m +1 647 885 4874Vice President, Investor Relations & Business Development
e [email protected]
www.serabigold.com
BEAUMONT CORNISH Limited
Nominated Adviser & Financial Adviser
Roland Cornish / Michael Cornish t +44 (0)20 7628 3396
PEEL HUNT LLP
Joint UK Broker
Ross Allister / Georgia Langoulant t +44 (0)20 7418 9000
TAMESIS PARTNERS LLP
Joint UK Broker
Charlie Bendon/ Richard Greenfield t +44 (0)20 3882 2868
CAMARCO
Financial PR – Europe
Gordon Poole / Emily Hall t +44 (0)20 3757 4980
Assay Results
Assay results reported within this release include those provided by the Company's own on-site laboratory facilities at Palito and have not yet been independently verified. Serabi closely monitors the performance of its own facility against results from independent laboratory analysis for quality control purpose. As a matter of normal practice, the Company sends duplicate samples derived from a variety of the Company's activities to accredited laboratory facilities for independent verification. Since mid-2019, over 10,000 exploration drill core samples have been assayed at both the Palito laboratory and certified external laboratory, in most cases the ALS laboratory in Belo Horizonte, Brazil. When comparing significant assays with grades exceeding 1 g/t gold, comparison between Palito versus external results record an average over-estimation by the Palito laboratory of 6.7% over this period. Based on the results of this work, the Company's management are satisfied that the Company's own facility shows sufficiently good correlation with independent laboratory facilities for exploration drill samples. The Company would expect that in the preparation of any future independent Reserve/Resource statement undertaken in compliance with a recognized standard, the independent authors of such a statement would not use Palito assay results without sufficient duplicates from an appropriately certificated laboratory.
Forward-looking statements
Certain statements in this announcement are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', 'should' ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. Several factors could cause actual results to differ materially from the results discussed in the forward-looking statements including risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets, reliance on key personnel, uninsured and underinsured losses and other factors, many of which are beyond the control of the Company. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements.
Qualified Persons Statement
The scientific and technical information contained within this announcement has been reviewed and approved by Michael Hodgson, a Director of the Company. Mr Hodgson is an Economic Geologist by training with over 30 years' experience in the mining industry. He holds a BSc (Hons) Geology, University of London, a MSc Mining Geology, University of Leicester and is a Fellow of the Institute of Materials, Minerals and Mining and a Chartered Engineer of the Engineering Council of UK, recognizing him as both a Qualified Person for the purposes of Canadian National Instrument 43-101 and by the AIM Guidance Note on Mining and Oil & Gas Companies dated June 2009.
Notice
Beaumont Cornish Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as nominated adviser to the Company in relation to the matters referred herein. Beaumont Cornish Limited is acting exclusively for the Company and for no one else in relation to the matters described in this announcement and is not advising any other person and accordingly will not be responsible to anyone other than the Company for providing the protections afforded to clients of Beaumont Cornish Limited, or for providing advice in relation to the contents of this announcement or any matter referred to in it.
Neither the Toronto Stock Exchange, nor any other securities regulatory authority, has approved or disapproved of the contents of this news release
See www.serabigold.com for more information and follow us on X @Serabi_Gold
APPENDIX
Mineral Reserves and Resources
The Company estimates and discloses mineral reserves and resources using the definitions adopted by the Canadian Institute of Mining, Metallurgy and Petroleum, and in accordance with NI 43-101. Further details are available at www.cim.org. See the 'Glossary of Geological and Mining Terms' for complete definitions of mineral reserves and mineral resources.
About Mineral Resources
Mineral resources are not mineral reserves and do not have demonstrated economic viability but do have reasonable prospect for economic extraction. They fall into three categories: measured, indicated, and inferred. The reported mineral resources are stated inclusive of mineral reserves. Measured and indicated mineral resources are sufficiently well-defined to allow geological and grade continuity to be reasonably assumed and permit the application of technical and economic parameters in assessing the economic viability of the mineral resource. Inferred mineral resources are estimated on limited information not sufficient to verify geological and grade continuity or to allow technical and economic parameters to be applied. Inferred mineral resources are too speculative geologically to have economic considerations applied to them. There is no certainty that mineral resources of any category will be upgraded to mineral reserves.
Important Information about Mineral Reserve and Resource Estimates
Whilst the Company takes all reasonable care in the preparation and verification of the mineral reserve and resource figures, the figures are estimates based in part on forward-looking information. Estimates are based on management's knowledge, mining experience, analysis of drilling results, the quality of available data and management's best judgment. They are, however, imprecise by nature, may change over time, and include many variables and assumptions including geological interpretation, commodity prices and currency exchange rates, recovery rates, and operating and capital costs. There is no assurance that the indicated levels of metal will be produced, and the Company may have to re-estimate the mineral reserves based on actual production experience. Changes in the metal price, production costs or recovery rates could make it unprofitable to operate or develop a particular deposit for a period of time.
A comparison of the updated Mineral Reserve Estimates as at 1 April 2025 with the previously reported Mineral Reserve Estimates as at 31 July 2023 published on 20 November 2023 is set out below. Comparison of Mineral Reserves for the Palito Mine, Para, Brazil April 2025 July 2023 Tonnes Grade Contained Tonnes Grade Contained (000's) (g/t Au) (000's oz) (000's) (g/t Au) (000's oz) Proven 422 7.7 103.8 568 8.1 147.5 Probable 224 6.0 43.1 197 6.8 43.2 Proven & Probable Reserves 646 7.1 147.0 765 7.8 190.7
A comparison of the updated Mineral Resource Estimates as at 1 April 2025 with the previously reported Mineral Resource Estimates as at 31 July 2023 published on 20 November 2023 is set out below. Comparison of Mineral Resources for the Palito Mine, Para, Brazil April 2025 July 2023 Tonnes Grade Contained Tonnes Grade Contained (000's) (g/t Au) (000's oz) (000's) (g/t Au) (000's oz) Measured Resources 769 10.8 268 772 11.0 274 Indicated Resources 333 7.7 83 243 8.4 66 Measured & Indicated Resources 1,102 9.9 350 1,015 10.4 339 Inferred Resources 682 7.4 162 674 7.0 152
GLOSSARY OF TERMS
The following is a glossary of technical terms: 'Ag' means silver. 'Au' means gold. 'assay' in economic geology, means to analyse the proportions of metal in a rock or overburden sample; to test an ore or mineral for composition, purity, weight or other properties of commercial interest. 'CIM' means the Canadian Institute of Mining, Metallurgy and Petroleum. 'chalcopyrite' is a sulphide of copper and iron. 'Cu' means copper. 'cut-off grade' the lowest grade of mineralised material that qualifies as ore in a given deposit; rock of the lowest assay included in an ore estimate. 'dacite porphyry intrusive' a silica-rich igneous rock with larger phenocrysts (crystals) within a fine-grained matrixi 'deposit' is a mineralised body which has been physically delineated by sufficient drilling, trenching, and/or underground work, and found to contain a sufficient average grade of metal or metals to warrant further exploration and/or development expenditures; such a deposit does not qualify as a commercially mineable ore body or as containing ore reserves, until final legal, technical, and economic factors have been resolved. 'electromagnetics' is a geophysical technique tool measuring the magnetic field generated by subjecting the sub-surface to electrical currents. 'garimpo' is a local artisanal mining operation 'garimpeiro' is a local artisanal miner. 'geochemical' refers to geological information using measurements derived from chemical analysis. 'geophysical' refers to geological information using measurements derived from the use of magnetic and electrical readings. 'geophysical techniques' include the exploration of an area by exploiting differences in physical properties of different rock types. Geophysical methods include seismic, magnetic, gravity, induced polarisation and other techniques; geophysical surveys can be undertaken from the ground or from the air. 'gossan' is an iron-bearing weathered product that overlies a sulphide deposit. 'grade' is the concentration of mineral within the host rock typically quoted as grams per tonne (g/t), parts per million (ppm) or parts per billion (ppb). 'g/t' means grams per tonne. 'granodiorite' is an igneous intrusive rock similar to granite. 'hectare' or a 'ha' is a unit of measurement equal to 10,000 square metres. 'igneous' is a rock that has solidified from molten material or magma. 'IP' refers to induced polarisation, a geophysical technique whereby an electric current is induced into the sub-surface and the conductivity of the sub-surface is recorded. 'intrusive' is a body of rock that invades older rocks. 'Indicated Mineral Resource An Indicated Mineral Resource is that part of a Mineral Resource for which quantity, grade or quality, densities, shape and physical characteristics are estimated with sufficient confidence to allow the application of Modifying Factors in sufficient detail to support mine planning and evaluation of the economic viability of the deposit. Geological evidence is derived from adequately detailed and reliable exploration, sampling and testing and is sufficient to assume geological and grade or quality continuity between points of observation. An Indicated Mineral Resource has a lower level of confidence than that applying to a Measured Mineral Resource and may only be converted to a Probable Mineral Reserve. 'Inferred Mineral Resource' An Inferred Mineral Resource is that part of a Mineral Resource for which quantity and grade or quality are estimated on the basis of limited geological evidence and sampling. Geological evidence is sufficient to imply but not verify geological and grade or quality continuity. An Inferred Mineral Resource has a lower level of confidence than that applying to an Indicated Mineral Resource and must not be converted to a Mineral Reserve. It is reasonably expected that the majority of Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration. 'Measured Mineral Resource' A Measured Mineral Resource is that part of a Mineral Resource for which quantity, grade or quality, densities, shape, and physical characteristics are estimated with confidence sufficient to allow the application of Modifying Factors to support detailed mine planning and final evaluation of the economic viability of the deposit. Geological evidence is derived from detailed and reliable exploration, sampling and testing and is sufficient to confirm geological and grade or quality continuity between points of observation. A Measured Mineral Resource has a higher level of confidence than that applying to either an Indicated Mineral Resource or an Inferred Mineral Resource. It may be converted to a Proven Mineral Reserve or to a Probable Mineral Reserve. 'mineralisation' the concentration of metals and their chemical compounds within a body of rock. 'mineralised' refers to rock which contains minerals e.g. iron, copper, gold. 'Mineral Resource' A Mineral Resource is a concentration or occurrence of solid material of economic interest in or on the Earth's crust in such form, grade or quality and quantity that there are reasonable prospects for eventual economic extraction. The location, quantity, grade or quality, continuity and other geological characteristics of a Mineral Resource are known, estimated or interpreted from specific geological evidence and knowledge, including sampling. 'Mineral Reserve' A Mineral Reserve is the economically mineable part of a Measured and/or Indicated Mineral Resource. It includes diluting materials and allowances for losses, which may occur when the material is mined or extracted and is defined by studies at Pre-Feasibility or Feasibility level as appropriate that include application of Modifying Factors. Such studies demonstrate that, at the time of reporting, extraction could reasonably be justified. 'Mo-Bi-As-Te-W-Sn' Molybdenum-Bismuth-Arsenic-Tellurium-Tungsten-Tin 'monzogranite' a biotite rich granite, often part of the later-stage emplacement of a larger granite body. 'mt' means million tonnes. 'ore' means a metal or mineral or a combination of these of sufficient value as to quality and quantity to enable it to be mined at a profit. 'oxides' are near surface bed-rock which has been weathered and oxidised by long term exposure to the effects of water and air. 'ppm' means parts per million. 'Probable Mineral Reserve' is the economically mineable part of an Indicated and, in some circumstances, a Measured Mineral Resource demonstrated by at least a Preliminary Feasibility Study. This Study must include adequate information on mining, processing, metallurgical, economic, and other relevant factors that demonstrate, at the time of reporting, that economic extraction can be justified. 'Proven Mineral Reserve' is the economically mineable part of a Measured Mineral Resource. A Proven Mineral Reserve implies a high degree of confidence in the Modifying Factors. 'saprolite' is a weathered or decomposed clay-rich rock. 'sulphide' refers to minerals consisting of a chemical combination of sulphur with a metal. 'vein' is a generic term to describe an occurrence of mineralised rock within an area of non-mineralised rock. 'VTEM' refers to versa time domain electromagnetic, a particular variant of time-domain electromagnetic geophysical survey to prospect for conductive bodies below surface. 'XRF' X-ray Fluorescence (XRF) is a spectrometric technique used to perform elemental analysis non-destructively on samples
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
23 minutes ago
- Business Wire
Paramount Deal Terms Force GAMCO to Receive Cash for its Voting Shares
GREENWICH, Conn.--(BUSINESS WIRE)--As of July 31, 2025, GAMCO Asset Management Inc. ('GAMCO'), an affiliate of GAMCO Investors, Inc. (OTCQX: GAMI), along with certain other affiliates, collectively owned approximately 12.0% of the outstanding class A voting stock of Paramount Global (NasdaqGS: PARAA) ('Paramount') on behalf of its clients. Given the terms of Paramount's pending combination with Skydance Media, in which current holders of the class A voting stock have no opportunity to continue to hold such voting stock, GAMCO is effectively being forced to receive cash for those shares. On July 31, 2025, GAMCO filed a 13D with the Securities and Exchange Commission disclosing it made a cash election under the terms of the transaction for all class A shares held. GAMCO Investors, Inc., through its subsidiaries, manages assets of private advisory accounts (GAMCO), mutual funds and closed-end funds (Gabelli Funds, LLC) and is known for its Private Market Value with a Catalyst™ style of investment.


Business of Fashion
an hour ago
- Business of Fashion
Oneskin Announces $20 Million Investment From Prelude Growth Partners
Oneskin, the longevity-focussed skincare brand based in California, has secured a $20 million investment from growth equity firm Prelude Growth Partners, the company announced on Wednesday. Prelude Growth Partners' investment buys out a former investor and will not dilute any other shareholders' equity. 'We were really impressed with Prelude immediately,' said Oneskin chief executive Carolina Reis Oliveira, adding that the firm had reached out with detailed plans and suggestions as to how a partnership could be fruitful. Oneskin was founded in 2021 by four Brazilian scientists and uses a proprietary peptide known as OS-01 which the company claims has unique anti-ageing properties. It offers products for the face, body and hair. Its primary channels are its own e-commerce site and Amazon; Reis Oliveira said more than two-third of its business are generated by subscriptions. Prelude Growth Partners' other beauty investments include the premium skin and body care lines Sol de Janeiro, Summer Fridays and Tower28. Two brands it invested in via the brand incubator The Center have now sold — skincare line Naturium to E.l.f Beauty in 2023, and fragrance maker Phlur to TSG Consumer Partners in July 2025. On Tuesday, it announced it has closed a third fund of $600 million earmarked for high-growth consumer brands. 'We're in a good place financially and have a good cushion in terms of cash,' said Reis Oliveira, adding that it will not need to raise again in the near future and that the funds will go towards a brand refresh, supporting clinical trials and on new hires. Oneskin recently appointed a vice president of growth marketing and a creative director, and will soon recruit a head of brand and chief marketing officer. The brand will continue to weigh up a retail entry for 2027 and invest in product development and marketing. Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis.
Yahoo
an hour ago
- Yahoo
Gynecological Devices Market Valuation to Reach US$ 20.19 Billion By 2033
Driven by an aging population and a strong shift toward minimally invasive procedures, the market is dominated by surgical devices and robotics. Hospitals and clinics remain primary end-users, investing heavily in advanced technology despite reimbursement pressures. Chicago, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The global gynecological devices market was valued at US$ 10.18 billion in 2024 and is expected to reach US$ 20.19 billion by 2033, growing at a CAGR of 7.90% during the forecast period 2025–2033. The global gynecological devices market is currently navigating a period of profound and accelerated transformation. This is not a gradual evolution but a dynamic surge, creating a landscape rich with opportunity for manufacturers, investors, and healthcare systems worldwide. A confluence of powerful drivers—including an unprecedented influx of venture capital into women's health technology, the escalating prevalence of complex gynecological conditions, and a wave of disruptive technological advancements—is fueling this robust growth. The market is moving beyond incremental improvements toward fundamental shifts in diagnostics and therapeutics. Free Report Sample Available for Immediate Download: An exhaustive analysis of data reveals a compelling, multi-layered narrative of expansion. This in-depth market research report dissects nine critical segments, presenting meticulously researched, data-driven insights that collectively illuminate the immense and multifaceted opportunities materializing across the global gynecological devices market. Key Finding in Gynecological Devices Market Market Forecast (2033) US$ 20.19 billion CAGR 7.90% Largest Region (2024) North America (42%) By Product Surgical Devices (53.0%) By End Users Hospitals & Clinics (65.26%) Top Drivers Rapidly aging female population creates a growing patient base. Government initiatives are increasingly focused on promoting women's health. High adoption of advanced and innovative medical technologies. Top Trends Rising physician preference for minimally invasive surgical techniques. Growing use of robotic-assisted surgery for gynecological procedures. Increased focus on early diagnostics with advanced imaging systems. Top Challenges Strict and lengthy regulatory approval cycles for new devices. Declining national birth rate impacting obstetrics device demand. Stringent reimbursement policies and pressure on healthcare cost containment. Venture Capital Investment Ignites a Firestorm of Femtech and Gynecological Device Innovation The financial landscape for women's health has been transformed by a massive surge of venture capital, directly spurring innovation and growth in the gynecological devices market. Funding for femtech startups has exceeded US$5 billion since 2020, with US$1.2 billion deployed in 2024 alone. Broadening the view to all women's health startups brings the 2024 total to US$2.6 billion, and, including all women-centric conditions, investment in the US and Europe reached nearly US$10.6 billion in 2024. This is a truly global trend. In Europe, €339.4 million was invested across 47 femtech deals in 2024, and European femtechs had already attracted over €334 million in venture capital by March 2025. This capital empowers companies to launch breakthrough products, fueling a new wave of innovation. Recent examples include Future Family securing a US$400 million financing program in April 2025 and ByHeart raising US$72 million the same month for manufacturing expansion. Significant 2025 investments underscore the diversity of innovation: Gesynta Pharma (US$29 million) and Conceivable Life Sciences (US$18 million) are advancing novel treatments, while Delfina (US$17 million), Twentyeight Health (US$10 million), and Teal Health (US$10 million) highlight the growing impact of AI-powered maternal health and accessible care. The funding cascade continues with Kegg (US$6.5 million), Egal (US$4 million), Fizimed (€4 million), Ema (US$3 million), Trellis Health (US$1.8 million), Raaz (US$1 million), Calla Lily (£1 million), Mabel (€600,000), Femble (€350,000), and AuraFem Health (US$200,000). The UNICEF Venture Fund further nurtures innovation, offering up to US$100,000 in equity-free funding for emerging economies, ensuring support at every level. Addressing Uterine Fibroids Creates a Significant and Highly Costly Market Opportunity Uterine fibroids represent a highly prevalent and economically significant condition, creating a vast and sustained demand for effective therapeutic solutions within the gynecological devices market. The sheer scale of this public health issue is immense. As of 2024, the estimated annual economic cost of uterine fibroids in the United States has escalated to an astonishing US$41.4 billion. A major component of this economic burden is productivity loss, with an estimated US$17.2 billion lost annually in the U.S. due to missed work and short-term disability. The patient population itself is expanding, with data showing that the number of women in the U.S. diagnosed with uterine fibroids increased by 10.6% between 2010 and 2022. This steady growth signals a consistently expanding patient base requiring treatment. The high out-of-pocket cost of traditional surgical interventions further amplifies the market need for innovative, less invasive, and more cost-effective devices. Without insurance coverage, a myomectomy procedure can cost between US$11,000 and US$22,000, while a full hysterectomy ranges from US$9,600 to US$24,000. Alternative, device-centric treatments also carry substantial price tags, with uterine artery embolization costing between US$10,000 and US$15,000, and radiofrequency ablation ranging from US$8,900 to US$20,000. These costs exhibit significant geographic variability; for instance, a laparoscopic hysterectomy could cost approximately US$28,000 in Cleveland, Ohio, while the same procedure in Atlanta, Georgia, might be closer to US$19,000. This cost-prohibitive environment creates a powerful incentive for the adoption of new technologies in the gynecological devices market that can offer superior outcomes at a lower total cost of care. Assisted Reproductive Technology Forges a Burgeoning and Profitable Niche Device Market The increasing societal demand for fertility assistance, driven by trends such as delayed parenthood and rising infertility rates, is a potent force shaping a specialized and highly profitable segment of the gynecological devices market. The global demand for these services is immense, with approximately 2.5 million In-Vitro Fertilization (IVF) cycles now being performed annually across the world. This trend is particularly pronounced in the United States, where the number of IVF cycles performed in SART (Society for Assisted Reproductive Technology) member clinics surged from 389,993 in 2022 to 432,641 in 2023. These procedures directly resulted in the birth of 95,860 babies in the U.S. in 2023. Comprehensive data from 2021 shows that 238,126 patients in the U.S. initiated a total of 413,776 ART cycles, demonstrating the high volume of procedures. The financial investment from patients is substantial and directly fuels demand for the sophisticated equipment, consumables, and diagnostic tools used in these delicate procedures. The average cost of a single IVF cycle in the U.S. ranges from US$12,000 to US$17,000, with some reports from the Department of Health and Human Services placing the potential cost between US$15,000 and US$20,000. This sustained, high-value patient expenditure ensures a robust and growing revenue stream for manufacturers of the specialized instruments essential to modern fertility treatment, making it a cornerstone of the modern gynecological devices market. Robotic Surgery Revolutionizes Gynecological Procedures and Propels Advanced System Device Adoption Minimally invasive robotic surgery has become the gold standard for many gynecological procedures, offering greater precision, shorter recovery times, and improved patient outcomes. This shift is driving rapid adoption of advanced robotic surgical systems, with the da Vinci system leading the market. In 2024 alone, 2,683,000 procedures were performed globally using da Vinci systems, reflecting exponential usage growth. Hardware sales surged as well, with 493 da Vinci surgical systems placed in healthcare facilities in Q4 2024, bringing full-year placements to 1,526. This expansion resulted in substantial financial gains: Intuitive Surgical reported US$2.41 billion in revenue for Q4 2024, up 25% from the previous year. Recurring revenue in the gynecological devices market from proprietary instruments and accessories climbed to US$1.41 billion in Q4, while capital sales of the systems hit US$1.97 billion for the full year. The da Vinci system generally sells for US$0.7 million to US$3.1 million, signifying significant capital commitment from hospitals. By 2020, over 5,500 da Vinci systems were installed in U.S. hospitals, with more than 2,000 hospitals nationwide now utilizing robotic surgery systems. This robust infrastructure supports continued growth: the global gynecological surgery robot market reached approximately US$3.2 billion in 2024 and is poised for further expansion. The outlook is especially strong given that nearly 600,000 hysterectomies are performed in the U.S. every year, many ideal for robotic assistance. Rising Prevalence of Pelvic and Endometrial Disorders Spurs Urgent Device Innovation A growing awareness among both patients and clinicians regarding the diagnosis and treatment of widespread yet historically underdiagnosed conditions such as endometriosis and pelvic organ prolapse (POP) is opening new frontiers for the gynecological devices market. The addressable patient population is substantial and expanding. Projections indicate that the number of American women suffering from at least one pelvic floor disorder is set to increase to 43.8 million by the year 2050. More specifically, the number of women with POP in the U.S. is expected to climb to 4.9 million by 2050, while the global population of POP patients is projected to reach an enormous 156 million by 2036. For endometriosis, a condition infamous for its diagnostic challenges, the average time from symptom onset to a definitive diagnosis is currently a staggering 8 years and 10 months. This diagnostic delay represents a critical unmet need and a clear opportunity for innovative diagnostic devices. Promising clinical research is underway to address these therapeutic gaps. A clinical trial involving 36 participants is evaluating a cannabidiol extract for endometriosis pain and is expected to conclude in December 2024, while another larger pain reduction trial with 102 participants is set to conclude in August 2024. Success in these trials could pave the way for new treatment paradigms supported by new devices. At-Home Testing Empowers Consumers and Rapidly Expands the Diagnostic Device Market A fundamental paradigm shift toward patient-centric care, emphasizing convenience, privacy, and empowerment, is fueling explosive growth in the at-home testing sector. This consumer-driven movement represents a critical expansion corridor for the diagnostic segment of the gynecological devices market. The market size reflects this rapid adoption; the global at-home testing market is estimated to reach a value of US$7,789.1 million in 2025, a healthy increase from its US$7,432.3 million valuation in 2024. The fertility testing sub-market is a particularly strong contributor to this growth, and it is estimated to be valued at US$672.9 million in 2025. Long-term projections are even more bullish, with the global Ovulation Test Market projected to expand to US$4.04 billion by 2032. Similarly, the broader global Fertility Testing Devices Market, which was valued at US$702.59 million in 2023, is projected to surge to an impressive US$1,171.55 million by 2032. The distribution channels for these devices are also modernizing to meet consumer demand. The online pharmacy segment has emerged as the dominant channel, holding the largest share of the fertility testing devices market in 2023 at 41.12%. This trend opens up a powerful direct-to-consumer channel, reshaping marketing and logistics for the entire gynecological devices market. Core Surgical and Diagnostic Device Advancements Enhance Overall Patient Care Efficacy Relentless and continuous innovation in the design and function of core surgical and diagnostic instruments remains a fundamental pillar of growth for the gynecological devices market. These advancements directly translate into improved clinical efficacy, enhanced safety profiles, and better patient experiences. A landmark development occurred in 2025 when Kephera Diagnostics launched its EndomTest, which stands as the first commercially available non-invasive blood test for endometriosis in the United States. This represents a significant leap forward in diagnostics. Simultaneously, the regulatory environment is adapting to support and safeguard this innovation. In November 2024, the Food and Drug Administration (FDA) announced a new communications pilot program specifically designed to enhance the medical device recall process, a program that explicitly includes obstetrics and gynecology devices. This heightened focus on safety is critical, as evidenced by an April 2024 recall of Boston Scientific's Obsidio Embolic device. A comprehensive review of high-risk recalls from 2002 through 2016 identified 7 distinct class I recall events that affected over 88,000 women's health medical devices. This history informs the current proactive regulatory stance, which ultimately fosters greater trust and ensures the long-term, sustainable health of the gynecological devices market. Tailor This Report to Your Specific Business Needs: The Staggering Economic Burden of Gynecological Conditions Underscores Urgent Device Need The immense economic weight imposed by common gynecological conditions on healthcare systems, employers, and patients provides a powerful and persuasive argument for the value proposition of effective and cost-efficient medical devices. The annual economic burden of uterine fibroids in the U.S. is a clear example, estimated to be as high as US$41.4 billion. A major driver of this staggering cost is the impact on workforce productivity, with lost wages due to fibroids costing American women approximately US$17.2 billion every year. The economic drain extends beyond fibroids. The annual surgical costs in the U.S. for treating pelvic organ prolapse now exceed US$1.523 billion. These multi-billion-dollar figures create a compelling business case for payers and healthcare providers to aggressively invest in advanced gynecological devices. Devices that can reduce the need for expensive surgeries, shorten hospital stays, minimize recovery times, and mitigate long-term complications offer a clear and quantifiable return on investment. This powerful economic reality serves as a persistent and significant demand driver for the entire gynecological devices market. Global Gynecological Devices Market Major Players: Karl Storz SE & Co. KG Hologic Inc. Boston Scientific Corporation B. Braun Melsungen AG Becton, Dickinson and Company CONMED Corporation CooperSurgical Inc. Coloplast A/S Johnson & Johnson (Ethicon) Medtronic plc Olympus Corporation Stryker Corporation Richard Wolf GmbH Intuitive Surgical Teleflex Incorporated Minerva Surgical Inc. Lumenis Ltd. Other Prominent Players Market Segmentation: By Product Surgical Devices Gynecological Imaging Devices Portable Tools By End Use Hospital & Clinics Ambulatory Surgery Centers (ASCs) By Region North America Europe Asia Pacific Middle East Africa South America Explore the Report Before You Buy – Book a Walkthrough: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: